[Retracted] Clinical Value of Serum SIRT1 Combined with Uterine Hemodynamics in Predicting Disease Severity and Fetal Growth Restriction in Preeclampsia

Ge, Tong Jun; Kong, Jian Ying

doi:https://doi.org/10.1155/2023/1744625

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusion Data Availability Conflicts of Interest References Copyright Related Articles

Research Article Retraction

!

This article has been Retracted. To view the article details, please click the ‘Retraction’ tab above.

Special Issue

Nutraceuticals, Functional Foods, and Dietary Supplements as a Natural Immunomodulator

View this Special Issue

Research Article | Open Access

Volume 2023 | Article ID 1744625 | https://doi.org/10.1155/2023/1744625

[Retracted] Clinical Value of Serum SIRT1 Combined with Uterine Hemodynamics in Predicting Disease Severity and Fetal Growth Restriction in Preeclampsia

Tong Jun Ge¹and Jian Ying Kong²

Academic Editor: Bo Li

Received24 Jun 2022

Revised28 Jul 2022

Accepted29 Jul 2022

Published07 Apr 2023

Abstract

Objective. The sirtuin regulator 1-related enzyme (SIRT1) has been shown to play an important role in various pathophysiological processes. Our aim was to investigate the effect and correlation of serum SIRT1 combined with uterine hemodynamic parameters on disease severity and fetal uterine growth restriction in the progression of preeclampsia and to evaluate its clinical value as a potential marker. Methods. A total of 100 patients with preeclampsia who were hospitalized in Qufu Normal University Hospital from June 2017 to June 2021 were selected as the research objects. According to the severity, they were divided into the mild (62 cases) and severe groups (38 cases), and according to whether the fetal growth restriction was combined or not, they were divided into the combined fetal growth restriction group (56 cases) and the uncomplicated fetal growth restriction group (44 cases). Serum SIRT1 expression and uterine artery hemodynamic parameters were detected, and Spearman analysis was used to evaluate the association of serum SIRT1 expression and uterine artery hemodynamic parameters (the peak-to-trough ratio of arterial blood velocity, the pulsatility index, and the resistance index) with disease severity (systolic blood pressure, diastolic blood pressure, and random urinary protein levels) and fetal growth restriction (femoral length, biparietal diameter, head circumference, and neonatal weight); unsupervised principal component analysis (PCA), supervised partial least-squares discrimination analysis (PLS-DA), cluster heat map analysis, the receiver operating characteristic (ROC) curve, and the area under curve (AUC) were used to evaluate the diagnostic value of serum SIRT1 expression combined with uterine artery hemodynamic parameters in the severity of disease and fetal growth restriction in patients with preeclampsia. Results. Compared with patients with mild preeclampsia, serum SIRT1 expression was lower in patients with severe preeclampsia (), the arterial blood flow velocity peak-to-trough ratio, pulsatility index, and resistance index were higher (; ); and serum SIRT1 expression and uterine artery hemodynamic parameters were closely related to disease severity (; ). In addition, the expression of serum SIRT1 in patients with preeclampsia combined with fetal growth restriction was lower than patients without preeclampsia (); the peak-to-trough ratio of arterial blood flow velocity, the pulsatility index, and the resistance index were higher (); and serum SIRT1 expression and uterine artery hemodynamics were closely related to fetal growth restriction (). Unsupervised PCA analysis and supervised PLS-DA analysis showed that patients with different severity of disease and patients with or without fetal growth restriction were similar within the groups, and there were significant differences between the groups; cluster heat map analysis showed that the mild and severe groups were stratified clustering, and the combined fetal growth restriction group and the uncombined group were hierarchically clustered; ROC curve showed that the AUC of serum SIRT1 expression combined with uterine artery hemodynamic parameters was 0.776 in identifying the severity of preeclampsia and 0.956 in identifying the preeclampsia complicated by fetal growth restriction. Conclusion. Serum SIRT1 combined with uterine hemodynamic parameters in preeclampsia is closely related to disease severity and fetal growth restriction and is expected to become a potential biomarker for early clinical intervention in patients.

1. Introduction

Preeclampsia (PE) refers to an idiopathic disease after 20 weeks of gestation, which occurs in a multistage and multistep process, with clinical phenotypes such as increased blood pressure, abdominal pain, headache, nausea, and other symptoms [1, 2]. Symptoms such as renal failure, liver failure, and cardiac arrest can be complicated, and in severe cases, the safety of the mother and baby can be endangered [3, 4]. In recent years, the incidence of preeclampsia has gradually increased. According to relevant data, the incidence of preeclampsia can reach 7% [5]. Fetal growth restriction (FGR) is mainly due to the low invasive ability of trophoblast cells and poor remodeling of the uterine spiral artery, which leads to placental ischemia and hypoxia, which affects fetal development [6, 7]. Preeclampsia combined with FGR is relatively common, the onset of gestational age is generally earlier, the functional development of fetal organs is immature, and the incidence of adverse pregnancy outcomes is high [8, 9]. Until now, the diagnosis and treatment of patients with preeclampsia complicated by fetal growth restriction has always been the focus of clinical attention.

Sirtuins are a class of nicotinamide adenine dinucleotide (NAD+)-dependent sirtuins [10]. Under physiological conditions, sirtuins regulate the generation of reactive oxygen species by regulating the acylation/deacylation process of antioxidant enzymes such as SOD1 and SOD2 [11, 12]. It can also regulate the activation and transplantation of signaling pathways such as NF-κB and AKT through the same mechanism, thereby regulating the production of adenosine triphosphate and inflammatory factors, thereby participating in intracellular important physiological processes such as gene transcription, energy metabolism, and antioxidant defense that are important for maintaining the stability of the intracellular environment and normal pregnancy [13]. When the expression of sirtuins is downregulated, their protective effect is also weakened, which can induce abnormalities such as maintenance stress, excessive inflammatory response, and energy metabolism disorders, leading to the occurrence of pathological pregnancy such as preeclampsia, GDM, and ICP [14]. In addition to being closely associated with the abovementioned pathological pregnancies such as spontaneous preterm birth, preeclampsia, GDM, ICP, and fetal growth restriction, the sirtuins family is also altered in other pathological pregnancies such as pregnancy depression and hyperemesis gravidarum. Among them, the sirtuin regulator 1-related enzyme (SIRT1) has been shown to play an important role in various pathophysiological processes [15–17]. In addition, during pregnancy, the uterine artery will undergo some physiological changes. After pregnancy, the blood vessels will gradually straighten and thicken, and the blood flow rate will increase, showing a state of low resistance and high flow [18]. The kinetic parameters will decrease accordingly. Studies have shown that uterine artery hemodynamic parameters in patients with preeclampsia are significantly higher than those in normal pregnant women [19]. Ultrasound technology enables the noninvasive and real-time assessment of hemodynamic parameters in vital organs of pregnant women and fetuses [20]. However, till date, the roles of serum SIRT1 and uterine hemodynamics in the progression of preeclampsia are not fully understood. The aim of this study was to discover the effect and correlation of serum SIRT1 combined with uterine hemodynamic parameters on disease severity and fetal uterine growth restriction in the progression of preeclampsia and to evaluate its clinical value as a potential marker.

2. Materials and Methods

2.1. General Information

A total of 100 patients with preeclampsia who were hospitalized in Qufu Normal University Hospital from June 2017 to June 2021 and underwent cesarean section on alternative days were selected. The clinical data of all subjects were collected, including age, body mass index, gestational age, number of gestations, number of deliveries, systolic blood pressure, diastolic blood pressure, and random urine protein detection. This study complied with the Declaration of Helsinki and the relevant regulations of clinical trial research in China. All subjects signed an informed consent form or authorized their family members to sign before enrollment. The study was approved by the Ethics Committee of Qufu Normal University Hospital, and all sample collection met the requirements of quality management standards for clinical trial research.

2.2. Inclusion and Exclusion Criteria

Inclusion criteria are as follows: (1) meet the diagnostic criteria for preeclampsia in “Guidelines for the Diagnosis and Treatment of Hypertensive Disorders in Pregnancy (2020)”; (2) patients and their families choose to undergo cesarean delivery; (3) all patients are singletons; (4) age 24–40 years old; (5) pregnancy times ≤3 times. Exclusion criteria are as follows: (1) those conceived by assisted reproductive technology; (2) those with hypertension before pregnancy; (3) severe kidney disease, chronic hypertension, autoimmune disease, and liver disease; (4) gestational diabetes, placental abruption, and other obstetric complications.

2.3. Grading Criteria for Preeclampsia

The patients with preeclampsia were divided into the mild and severe groups according to the severity of the disease. The criteria for inclusion in the mild group are systolic blood pressure greater than or equal to 140 mmHg and/or diastolic blood pressure greater than or equal to 90 mmHg after 20 weeks of pregnancy, proteinuria greater than or equal to 0.3 g/24 h, or random urine proteins (+). The criteria for inclusion in the severe group are (if any of the following symptoms are present) pregnant women’s blood pressure continues to rise, systolic blood pressure is greater than or equal to 160 mmHg, and (or) diastolic blood pressure is greater than or equal to 100 mmHg; proteinuria is greater than or equal to 5 g/24 h or random urine proteins (+++); elevated levels of liver enzymes alanine aminotransferase or aspartate aminotransferase, abnormal liver function; urine output less than 17 mL/h or urine output less than 400 mL/24 h or serum creatinine greater than 10⁶ μmol/L, abnormal renal function; anemia, intravascular hemolysis, jaundice, or platelets less than 10¹¹/L; persistent upper abdominal pain, subcapsular hematoma, or liver rupture; persistent headache, visual disturbance, or other symptoms of cranial nerve injury; and oligohydramnios, embryonic growth limited.

2.4. Evaluation of Fetal Growth Restriction

According to the criteria of “Expert Consensus on Fetal Growth Restriction (2019 Edition),” patients with preeclampsia were divided into combined fetal growth restriction and nonfetal growth restriction. Four-dimensional color Doppler ultrasound was performed on pregnant women to record the femoral length, biparietal diameter, and head circumference of the fetus; after the fetus was born, the neonatal weight was recorded, and the birth weight of the fetus was less than 2 standard deviations of the average weight for gestational age or less than the 10^th percentile of normal weight for the same age.

2.5. Observation Indicators and Methods

2.5.1. Serum Sample Collection

A vacuum blood collection tube was used to collect 2 mL of cubital venous blood from the subjects, and the upper serum was collected by centrifugation. Set standards, samples to be tested and blank wells, refer to the steps in the kit instructions, and use the SIRT1 ELISA detection kit. The absorbance was detected by a microplate reader, and the standard curve was calculated from the absorbance of the standard to obtain the concentration of SIRT1 in serum samples.

2.5.2. Measurement of Uterine Artery Hemodynamic Parameters

Pregnant women were kept in the supine or lateral position, breathing calmly, and a GE Voluson E8 three-dimensional color Doppler ultrasound system (GE, USA) was used to explore the fetal structure, placenta, and amniotic fluid. The ultrasound probe was placed in the groin, CDFI was started, the sampling frame was placed above the intersection of the uterine artery and the external iliac artery, and 1 cm away from the external iliac artery, the sampling volume was 2 mm, and the angle between the sampling line and the blood flow direction was <60°. Uterine artery blood flow parameters were measured, including arterial systolic peak flow velocity (S) and diastolic flow velocity (D). Time-averaged peak flow velocity (TAPV) was the time-averaged peak blood flow velocity in a cardiac cycle. We calculated the pulsatility index (PI) = (S − D)/TAPV, the resistance index (RI) = (S − D)/S, and the peak-to-valley ratio of blood flow velocity = S/D.

2.6. Statistical Analysis

SPSS 22.0 statistical software was used to analyze and process the data, and GraphPad 8.0 software was used for drawing. The t-test was used for comparison between the two groups. ROC analysis was performed for serum SIRT1 expression combined with uterine artery hemodynamic parameters to identify the severity of preeclampsia and the fetal growth restriction. Spearman analysis was used to evaluate the association of serum SIRT1 expression and uterine artery hemodynamic parameters with disease severity and fetal growth restriction. was considered statistically significant.

3. Results

3.1. Comparison of Clinical Data

The 100 patients with preeclampsia were graded according to the severity. There were 62 patients with mild preeclampsia and 38 patients with severe preeclampsia. The levels of systolic blood pressure (168.55 ± 5.08) mmHg, diastolic blood pressure (118.13 ± 9.73) mmHg, and random proteins (168.55 ± 5.08) g/24 h in the severe preeclampsia group were higher than those in the mild group () (Table 1). There were no significant differences in age, body weight, gestational age, number of pregnancies, and number of deliveries between the two groups (Table 1).

In addition, according to whether the 100 patients with preeclampsia were complicated with fetal growth restriction, there were 56 cases with fetal growth restriction and 44 cases without fetal growth restriction. Femoral length, biparietal diameter, head circumference, and neonatal weight in the combined fetal growth restriction group were lower than those in the uncomplicated fetal growth restriction group () (Table 2). There were no significant differences in age, body weight, gestational age, number of pregnancies, and number of deliveries between the two groups (Table 2).

3.2. Comparison of the Serum SIRT1 Expression and Uterine Artery Hemodynamics

We detected serum SIRT1 expression in all patients. The results showed that the expression of serum SIRT1 in patients with severe preeclampsia decreased compared with the mild group () (Figure 1(a)); the peak-to-trough ratio of blood flow velocity, the pulsatility index, and the resistance index were all increased in patients with severe preeclampsia compared with the mild group (; ) (Figures 1(b)–1(d)). In addition, the expression of serum SIRT1 was decreased in patients with preeclampsia combined with fetal growth restriction compared with the combined group () (Figure 2(a)); the peak-to-trough ratio of arterial blood flow velocity, the pulsatility index, and the resistance index were all increased in patients with preeclampsia combined with fetal growth restriction compared with the uncombined group () (Figures 2(b)–2(d)). These results suggest that serum SIRT1 expression and uterine artery hemodynamic parameters may be closely related to the severity of preeclampsia and the presence of fetal growth restriction.

(a)

(b)

(c)

(d)

(a)

(b)

(c)

(d)

3.3. Correlation Analysis of Serum SIRT1 Expression and Uterine Artery Hemodynamics with Disease Severity

To examine the relationship between serum SIRT1 expression and uterine artery hemodynamics and disease severity, Spearman correlation analysis was further performed, and the results showed that serum SIRT1 expression was negatively correlated with systolic blood pressure, diastolic blood pressure, and random urinary protein levels (; ) (Figure 3); the arterial blood flow velocity peak-to-trough ratio, pulsatility index, and resistance index were positively correlated with systolic blood pressure, diastolic blood pressure, and random urinary protein levels (; ) (Figure 3). These results suggest that serum SIRT1 expression and uterine artery hemodynamics are closely related to the severity of preeclampsia.

3.4. Correlation Analysis of Serum SIRT1 Expression and Uterine Artery Hemodynamics with Fetal Growth Restriction

To examine the relationship between serum SIRT1 expression and uterine artery hemodynamics and fetal growth restriction, Spearman correlation analysis was further performed, and the results showed that serum SIRT1 expression was positively correlated with femoral length, biparietal diameter, head circumference, and neonatal weight () (Figure 4); the arterial blood flow velocity peak-to-trough ratio, pulsatility index, and resistance index were negatively correlated with femoral length, biparietal diameter, head circumference, and neonatal weight () (Figure 4). These results suggest that serum SIRT1 expression and uterine artery hemodynamics are closely related to preeclampsia complicated by fetal growth restriction.

3.5. The Diagnostic Value of Serum SIRT1 Expression Combined with Uterine Artery Hemodynamics in Predicting Disease Severity

Unsupervised PCA analysis of the severity of preeclampsia with serum SIRT1 expression combined with uterine arterial hemodynamics showed that groups of different severity tended to be clustered and tended to be discrete (Figure 5(a)). The PLS-DA analysis also showed that the mild group and the severe group were significantly separated in the PC1 dimension, suggesting that the patients with different severity of preeclampsia were similar within the group and significantly different between the groups (Figure 5(b)). The heat map of cluster analysis showed that the mild group and the severe group were hierarchically clustered, suggesting that serum SIRT1 expression combined with uterine artery hemodynamic parameters could discriminate disease severity in patients with preeclampsia (Figure 5(c)).

(a)

(b)

(c)

Figure 5

Discriminant analysis of serum SIRT1 expression combined with uterine artery hemodynamic parameters on the severity of preeclampsia. (a) PCA analysis of serum SIRT1 expression combined with uterine artery hemodynamic parameters in patients with different severity of preeclampsia; (b) PLS-DA analysis of serum SIRT1 expression combined with uterine artery hemodynamic parameters in patients with different severity of preeclampsia; (c) cluster heat map of serum SIRT1 expression and hemodynamic parameters of uterine artey in patients with preeclampsia of different severity.

3.6. The ROC Curve of Serum SIRT1 Expression Combined with Uterine Artery Hemodynamics in Predicting Disease Severity

The diagnostic value of serum SIRT1 expression combined with uterine artery hemodynamic parameters in the diagnosis of disease severity in patients with preeclampsia was analyzed by using the ROC curve and AUC. The results showed that the AUC value of serum SIRT1 expression combined with uterine artery hemodynamic parameters (AUC = 0.776) was higher than that of serum SIRT1 expression (AUC = 0.750) and the uterine artery hemodynamic flow velocity peak-to-trough ratio (AUC = 0.704) (Figure 6), suggesting that serum SIRT1 expression combined with uterine artery hemodynamic parameters has a high diagnostic value for the severity of preeclampsia.

3.7. The Diagnostic Value of Serum SIRT1 Expression Combined with Uterine Artery Hemodynamics in Predicting Fetal Growth Restriction

Unsupervised PCA analysis of fetal growth restriction in preeclampsia with serum SIRT1 expression combined with uterine artery hemodynamics showed that the groups tended to be clustered and tended to be discrete (Figure 7(a)). The PLS-DA analysis also showed that the group with fetal growth restriction and the uncombined group were significantly separated in the PC1 dimension, suggesting that the preeclampsia patients with or without fetal growth restriction were similar within the group, and the difference between the groups was significant (Figure 7(b)). The cluster analysis heat map showed that the combined and uncombined groups were hierarchically clustered, suggesting that serum SIRT1 expression combined with uterine artery hemodynamic parameters could differentiate fetal growth restriction in patients with preeclampsia (Figure 7(c)).

(a)

(b)

(c)

3.8. The ROC Curve of Serum SIRT1 Expression Combined with Uterine Artery Hemodynamics in Predicting Fetal Growth Restriction

The diagnostic value of serum SIRT1 expression combined with uterine artery hemodynamic parameters for fetal growth restriction in patients with preeclampsia was analyzed by the ROC curve and AUC. The results showed that the AUC value of serum SIRT1 expression combined with uterine artery hemodynamic parameters (AUC = 0.956) was higher than that of serum SIRT1 expression (AUC = 0.941) and the uterine artery hemodynamic flow velocity peak-to-trough ratio (AUC = 0.910) (Figure 8), suggesting that serum SIRT1 expression combined with uterine artery hemodynamic parameters has a high diagnostic value for fetal growth restriction in preeclampsia.

4. Discussion

In early pregnancy, trophoblasts invade the uterine spiral artery, remodel the uterine spiral artery, ensure the placenta engineering, and provide nutrients for the fetus [21]. Preeclampsia pregnant women have insufficient trophoblast invasion in early pregnancy, which leads to the disorder of uterine spiral artery remodeling and abnormal placenta formation, which lays a hidden danger for the occurrence and development of preeclampsia; the placental blood perfusion is insufficient, and placental ischemia and hypoxia will release cells Toxic substances enter the blood, further causing oxidative stress and vascular endothelial injury [22]. When the condition worsens, the uterine spiral artery experiences atherosclerosis, and the placental perfusion is further reduced and induces thrombosis and placental infarction. The severity of preeclampsia is associated with maternal and neonatal morbidity and thus mortality. Untreated preeclampsia may have serious complications, such as eclampsia, liver rupture, stroke, pulmonary edema, or renal failure, which are all fatal complications and are also associated with fetal prognosis, placental abruption, fetal growth increased risk of restriction, preterm birth, and stillbirth. Whether spontaneous or iatrogenic, neonates with preeclampsia may develop bronchopulmonary dysplasia and cerebral palsy. Preeclampsia may reduce the quality of health of the newborn and increase the risk of postpartum depression. In addition, preeclampsia and fetal growth restriction share common pathophysiological features, both of which are placental diseases [23]. Preeclampsia is also an independent risk factor for fetal growth restriction, and fetal growth restriction is a serious complication of preeclampsia [24]. At present, the pathogenesis of preeclampsia is still unclear, and specific clinical indicators are still lacking to predict the severity of preeclampsia and fetal growth restriction. Therefore, theoretically, if multiple disease-related biological indicators are combined, the sensitivity and specificity of prediction can be improved to a certain extent [25, 26]. We explored the clinical value of serum SIRT1 combined with uterine hemodynamics in preeclampsia in predicting disease severity and fetal growth restriction.

Trophoblast invasion is regulated by various pathways and factors, among which SIRT1 is involved in regulating various biological processes [27]. SIRT1, a member of the NAD + -dependent protein deacetylase family and a nutrient sensor, was originally discovered in the genome of budding Saccharomyces cerevisiae, a gene that regulates lifespan and was first identified as a histone deacetylase that promotes chromatin compaction and thus silences the genome during nutrient deprivation [28]. Studies have found that SIRT1 can negatively regulate the nuclear factor kappa B (NF-κB) signaling pathway involved in the inflammatory process by activating the extracellular regulated protease (ERK) pathway, inhibiting the validation response of human granulosa cells and oocytes, and exerting an antiapoptotic effect [29]. Maternal SIRT1 deficiency results in defective offspring embryo development during mouse embryonic development [30]. Our study found that patients with severe preeclampsia had increased systolic blood pressure, diastolic blood pressure, and random protein levels, and decreased serum SIRT1 expression, femoral length, biparietal diameter, head circumference, and neonatal weight in patients with preeclampsia complicated by fetal growth restriction. Serum SIRT1 expression was decreased in patients with preeclampsia, suggesting that serum SIRT1 expression may be closely related to the severity of preeclampsia and fetal growth restriction. We further conducted Spearman correlation analysis and found that serum SIRT1 expression was negatively correlated with systolic blood pressure, diastolic blood pressure, and the random urine protein content and was positively correlated with femur length, biparietal diameter, head circumference, and neonatal weight, confirming our previous assumptions.

In addition, ultrasound Doppler analysis can detect evidence of impaired uterine artery blood flow and placental perfusion before clinical manifestations of preeclampsia appear and has become an effective method to predict adverse pregnancy outcomes such as preeclampsia [31]. Uterine artery blood flow can reflect the hemodynamic status of the mother. Under normal circumstances, in order to ensure the blood supply of the uterus and placenta, the uterine artery blood flow resistance will gradually decrease from the beginning of pregnancy, but this is not conducive to spiral artery remodeling in patients with preeclampsia, the uteroplacental circulation resistance increases, which in turn causes the uterine artery resistance to increase [32]. Our study found that the peak-to-trough ratio of arterial blood flow velocity, the pulsatility index, and the resistance index were increased in patients with severe preeclampsia, and the peak-to-trough ratio of arterial blood flow velocity, the pulsatility index, and the resistance index in patients with preeclampsia complicated with fetal growth restriction were also elevated, suggesting that uterine artery hemodynamic parameters may also be closely related to the severity of preeclampsia and the presence of fetal growth restriction. We further conducted Spearman correlation analysis and found that the peak-to-trough ratio of arterial blood flow velocity, the pulsatility index, and the resistance index were positively correlated with systolic blood pressure, diastolic blood pressure, and the random urine protein content and were negatively correlated with femur length, biparietal diameter, head circumference, and neonatal body weights, which also confirmed our earlier hypothesis.

To evaluate the diagnostic and predictive value of serum SIRT1 expression combined with uterine artery hemodynamics, we performed unsupervised PCA analysis, supervised PLS-DA analysis, and cluster heatmap analysis and found that serum SIRT1 expression combined with uterine artery hemodynamics can effectively distinguish the disease severity and complicated fetal growth restriction in patients with preeclampsia. The diagnostic value of serum SIRT1 expression combined with uterine artery hemodynamic parameters was further analyzed by the ROC curve and AUC that has a high diagnostic value.

5. Conclusion

Serum SIRT1 combined with uterine hemodynamic parameters in preeclampsia is closely related to disease severity and fetal growth restriction and is expected to become a potential biomarker for early clinical intervention in patients.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors have no conflicts of interest to declare.

References

R. Nirupama, S. Divyashree, P. Janhavi, S. P. Muthukumar, and P. V. Ravindra, “Preeclampsia: pathophysiology and management,” Journal of Gynecology Obstetrics and Human Reproduction, vol. 50, no. 2, Article ID 101975, 2021.
View at: Publisher Site | Google Scholar
T. Raia-Barjat, O. Edebiri, and F. Ni Ainle, “Preeclampsia and venous thromboembolism: pathophysiology and potential therapy,” Front Cardiovasc Med, vol. 9, Article ID 856923, 2022.
View at: Publisher Site | Google Scholar
D. Zheng, M. Khan, G. Zhang et al., “A bibliometric analysis of the research on preeclampsia in the first two decades of the twenty-first century,” Journal of Hypertension, vol. 40, no. 6, pp. 1126–1164, 2022.
View at: Publisher Site | Google Scholar
E. Jung, R. Romero, L. Yeo et al., “The etiology of preeclampsia,” American Journal of Obstetrics and Gynecology, vol. 226, no. 2, pp. S844–S866, 2022.
View at: Publisher Site | Google Scholar
M. A. Bright, M. Parrott, S. Martin, L. Thompson, D. Roussos-Ross, and D. Montoya-Williams, “Streamlining universal prenatal screening for risk for adverse birth outcomes,” Maternal and Child Health Journal, vol. 26, no. 5, pp. 1022–1029, 2022.
View at: Publisher Site | Google Scholar
M. Kasuya, N. Akiba, T. Iriyama et al., “The impact of fetal growth restriction in diagnosing preeclampsia on the severity of maternal features,” Journal of Obstetrics and Gynaecology Research, vol. 48, no. 4, pp. 912–919, 2022.
View at: Publisher Site | Google Scholar
C. Paules, A. P. Dantas, J. Miranda et al., “Premature placental aging in term small-for-gestational-age and growth-restricted fetuses,” Ultrasound in Obstetrics and Gynecology, vol. 53, no. 5, pp. 615–622, 2019.
View at: Publisher Site | Google Scholar
S. Amodeo, P. I. Cavoretto, A. Seidenari et al., “Second trimester uterine arteries pulsatility index is a function of placental pathology and provides insights on stillbirth aetiology: a multicenter matched case-control study,” Placenta, vol. 121, pp. 7–13, 2022.
View at: Publisher Site | Google Scholar
B. A. Nowakowska, K. Pankiewicz, U. Nowacka, M. Niemiec, S. Kozłowski, and T. Issat, “Genetic background of fetal growth restriction,” International Journal of Molecular Sciences, vol. 23, no. 1, p. 36, 2021.
View at: Publisher Site | Google Scholar
C. K. Singh, G. Chhabra, M. A. Ndiaye, L. M. Garcia-Peterson, N. J. Mack, and N. Ahmad, “The role of sirtuins in antioxidant and redox signaling,” Antioxidants and Redox Signaling, vol. 28, no. 8, pp. 643–661, 2018.
View at: Publisher Site | Google Scholar
H. Yu, Y. Zhang, M. Liu, L. Liao, X. Wei, and R. Zhou, “SIRT3 deficiency affects the migration, invasion, tube formation and necroptosis of trophoblast and is implicated in the pathogenesis of preeclampsia,” Placenta, vol. 120, pp. 1–9, 2022.
View at: Publisher Site | Google Scholar
M. Wang and H. Lin, “Understanding the function of mammalian sirtuins and protein lysine acylation,” Annual Review of Biochemistry, vol. 90, no. 1, pp. 245–285, 2021.
View at: Publisher Site | Google Scholar
A. Sakowicz, “The targeting of nuclear factor kappa B by drugs adopted for the prevention and treatment of preeclampsia,” International Journal of Molecular Sciences, vol. 23, no. 5, p. 2881, 2022.
View at: Publisher Site | Google Scholar
A. Colloca, A. Balestrieri, C. Anastasio, M. L. Balestrieri, and N. D’Onofrio, “Mitochondrial sirtuins in chronic degenerative diseases: new metabolic targets in colorectal cancer,” International Journal of Molecular Sciences, vol. 23, no. 6, p. 3212, 2022.
View at: Publisher Site | Google Scholar
R. Nogueiras, K. M. Habegger, N. Chaudhary et al., “Sirtuin 1 and sirtuin 3: physiological modulators of metabolism,” Physiological Reviews, vol. 92, no. 3, pp. 1479–1514, 2012.
View at: Publisher Site | Google Scholar
Y. Huang, X. D. Zheng, and H. Li, “Protective role of SIRT1-mediated Sonic Hedgehog signaling pathway in the preeclampsia rat models,” Journal of Assisted Reproduction and Genetics, vol. 38, no. 7, pp. 1843–1851, 2021.
View at: Publisher Site | Google Scholar
S. Viana-Mattioli, P. Nunes, R. Cavalli, and V. Sandrim, “Analysis of SIRT1 expression in plasma and in an in vitro model of preeclampsia,” Oxidative Medicine and Cellular Longevity, vol. 2020, Article ID 4561083, 7 pages, 2020.
View at: Publisher Site | Google Scholar
J. J. Rodriguez-Fernandez, L. E. Martinez-Garza, G. Sepulveda-Gonzalez, F. Hernandez-Castro, and T. Gaston-Locsin, “Serum biomarkers and Doppler pulsatile index increases likelihood ratio for prediction of preeclampsia in the second trimester of pregnancy,” Journal of Obstetrics and Gynaecology, vol. 42, pp. 1722–1727, 2022.
View at: Publisher Site | Google Scholar
Y. Tian and X. Yang, “A review of roles of uterine artery Doppler in pregnancy complications,” Frontiers of Medicine, vol. 9, Article ID 813343, 2022.
View at: Publisher Site | Google Scholar
F. Trottmann, A. E. Mollet, S. Amylidi-Mohr, D. Surbek, L. Raio, and B. Mosimann, “Integrating combined first trimester screening for preeclampsia into routine ultrasound examination,” Geburtshilfe und Frauenheilkunde, vol. 82, no. 3, pp. 333–340, 2022.
View at: Publisher Site | Google Scholar
A. Natenzon, P. McFadden, S. C. DaSilva-Arnold, S. Zamudio, and N. P. Illsley, “Diminished trophoblast differentiation in early onset preeclampsia,” Placenta, vol. 120, pp. 25–31, 2022.
View at: Publisher Site | Google Scholar
S. Suresh, C. Amegashie, E. Patel, K. M. Nieman, and S. Rana, “Racial disparities in diagnosis, management, and outcomes in preeclampsia,” Current Hypertension Reports, vol. 24, no. 4, pp. 87–93, 2022.
View at: Publisher Site | Google Scholar
P. Z. Mkhize, W. N. Phoswa, O. P. Khaliq, V. Dorsamy, and J. Moodley, “Aspirin in the prevention of preeclampsia: a protocol for systematic review and meta analysis,” Medicine (Baltimore), vol. 100, no. 48, Article ID e27916, 2021.
View at: Publisher Site | Google Scholar
M. Takahashi, S. Makino, K. Oguma et al., “Fetal growth restriction as the initial finding of preeclampsia is a clinical predictor of maternal and neonatal prognoses: a single-center retrospective study,” BMC Pregnancy and Childbirth, vol. 21, no. 1, p. 678, 2021.
View at: Publisher Site | Google Scholar
M. Yao, Y. Xiao, Z. Yang et al., “Identification of biomarkers for preeclampsia based on metabolomics,” Clinical Epidemiology, vol. 14, pp. 337–360, 2022.
View at: Publisher Site | Google Scholar
J. M. Hendershot, M. Abbasi, L. Fortier et al., “Analytical validation of a novel panel of biomarkers for a test for preeclampsia,” Journal of Pharmaceutical and Biomedical Analysis, vol. 214, Article ID 114729, 2022.
View at: Publisher Site | Google Scholar
K. M. Lee, H. W. Seo, M. S. Kwon, A. R. Han, and S. K. Lee, “SIRT1 negatively regulates invasive and angiogenic activities of the extravillous trophoblast,” American Journal of Reproductive Immunology, vol. 82, no. 4, Article ID e13167, 2019.
View at: Publisher Site | Google Scholar
H. C. Chang and L. Guarente, “SIRT1 and other sirtuins in metabolism,” Trends in Endocrinology and Metabolism, vol. 25, no. 3, pp. 138–145, 2014.
View at: Publisher Site | Google Scholar
J. Pham, K. Arul Nambi Rajan, P. Li, and M. M. Parast, “The role of Sirtuin1-PPARγ axis in placental development and function,” Journal of Molecular Endocrinology, vol. 60, no. 4, pp. R201–R212, 2018.
View at: Publisher Site | Google Scholar
A. J. Broady, M. H. Loichinger, H. J. Ahn, P. M. Davy, R. C. Allsopp, and G. D. Bryant-Greenwood, “Protective proteins and telomere length in placentas from patients with pre-eclampsia in the last trimester of gestation,” Placenta, vol. 50, pp. 44–52, 2017.
View at: Publisher Site | Google Scholar
N. Furuya, J. Hasegawa, M. Doi, J. Koike, and N. Suzuki, “Accuracy of prenatal ultrasound in evaluating placental pathology using superb microvascular imaging: a prospective observation study,” Ultrasound in Medicine and Biology, vol. 48, no. 1, pp. 27–34, 2022.
View at: Publisher Site | Google Scholar
C. Bertholdt, G. Hossu, C. Banasiak, M. Beaumont, and O. Morel, “First trimester screening for pre-eclampsia and intrauterine growth restriction using three-dimensional Doppler angiography (SPIRIT): protocol for a multicentre prospective study in nulliparous pregnant women,” BMJ Open, vol. 10, no. 10, Article ID e037751, 2020.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2023 Tong Jun Ge and Jian Ying Kong. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies